Secukinumab
- Generic Name
- Secukinumab
- Brand Names
- Cosentyx
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1229022-83-6
- Unique Ingredient Identifier
- DLG4EML025
- Background
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Fo...
- Indication
Secukinumab is indicated the treatment of moderate to severe plaque psoriasis in patients six years and older who are candidates for systemic therapy or phototherapy. In Europe, the drug is used in children and adolescents six to 18 years of age for this indication.
...
- Associated Conditions
- Enthesitis Related Arthritis (ERA), Juvenile Idiopathic Arthritis (JIA), Juvenile psoriatic arthritis, Non-radiographic Axial Spondyloarthritis, Severe Plaque psoriasis, Active Ankylosing spondylitis, Active Psoriatic arthritis, Moderate Plaque psoriasis
- Associated Therapies
- -
Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT02595970
- Locations
- 🇫🇷
Novartis Investigative Site, Toulouse Cedex, France
Secukinumab for Treatment of Atopic Dermatitis
- First Posted Date
- 2015-11-01
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 41
- Registration Number
- NCT02594098
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Immunologic Response to Secukinumab in Plaque Psoriasis
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 15
- Registration Number
- NCT02592018
- Locations
- 🇺🇸
UCSF Psoriasis and Skin Treatment Center, San Francisco, California, United States
Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 151
- Registration Number
- NCT02559622
- Locations
- 🇩🇪
Novartis Investigative Site, Ulm, Germany
Psoriasis-Arthritis & Bone Program
- First Posted Date
- 2015-06-26
- Last Posted Date
- 2019-09-27
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 40
- Registration Number
- NCT02483234
- Locations
- 🇩🇪
University of Erlangen-Nuremberg, Erlangen, Germany
Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis
- First Posted Date
- 2015-06-17
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 772
- Registration Number
- NCT02474069
- Locations
- 🇩🇪
Novartis Investigative Site, Wuppertal, Germany
Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2014-05-22
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- University of Athens
- Target Recruit Count
- 200
- Registration Number
- NCT02144857
- Locations
- 🇬🇷
Attikon Hospital, Athens, Greece
Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 5
- Registration Number
- NCT02044848
- Locations
- 🇺🇸
Novartis Investigative Site, Seattle, Washington, United States
16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
- Conditions
- Interventions
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 226
- Registration Number
- NCT02008916
- Locations
- 🇬🇧
Novartis Investigative Site, Torquay, United Kingdom
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
- First Posted Date
- 2013-07-04
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 460
- Registration Number
- NCT01892436
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.